<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899171</url>
  </required_header>
  <id_info>
    <org_study_id>S9031-S9126-S9333-S9500-A</org_study_id>
    <secondary_id>S9031-S9126-S9333-S9500-A</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00899171</nct_id>
  </id_info>
  <brief_title>S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>S9031-S9126-S9333-S9500-A, Examination of the Prognostic Significance of AML-Specific and Age-Associated Genes in AML Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of bone marrow and blood in the laboratory from patients with
      cancer may help doctors learn more about changes that occur in DNA and identify biomarkers
      related to cancer.

      PURPOSE: This research study is looking at bone marrow and blood samples from patients with
      acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine whether the expression of previously identified acute myeloid leukemia
           (AML)-specific and age-associated genes have prognostic significance in adult patients
           with AML.

        -  To examine, preliminarily, if AML-specific and age-associated expression changes occur
           in the most primitive hematopoietic leukemia blasts (i.e., CD34+/38-).

        -  To examine, preliminarily, whether methylation or histone modification of the IRF8 CPG
           island/promoter region is correlated with IRF8 gene expression in AML.

      OUTLINE: This is a multicenter study.

      Previously collected specimens of RNA from pre-treatment marrow or peripheral blood are
      obtained from a repository of SWOG clinical trials (SWOG-S9031, SWOG-9126, SWOG-9333, and
      SWOG-9500). Samples are analyzed for absolute expression levels of 23 selected genes and
      relative expression levels of splice variants via quantitative RT/PCR and GeneScan assays and
      linked to clinical and outcome data from the main SWOG database. Samples from a subset of
      patients are analyzed to confirm aberrant expression of acute myeloid leukemia-specific and
      age-associated genes in highly enriched population of leukemic blasts (CD34+/CD38- and
      CD34+/CD38+). DNA samples are also analyzed for correlation of IRF8 gene expression with
      methylation or histone modification of the IRF8 CPG island/promoter region.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic significance for complete response, overall survival, and relapse-free survival of total and relative expression levels (variant/wild type ratios) for each gene</measure>
    <time_frame>immediate</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Role of acute myeloid leukemia (AML)-specific and age-associated genes in the biology and prognosis of AML</measure>
    <time_frame>immediate</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Role of methylation and histone modification in IRF8 gene expression</measure>
    <time_frame>immediate</time_frame>
  </primary_outcome>
  <enrollment type="Actual">251</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolled on S9031, S9333, S0106 or S0112 that consented to use of specimens for
        future research
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Pretreatment RNA specimens* available from patients with acute myeloid leukemia (AML)
             registered for front-line therapy on the following clinical trials:

               -  SWOG-9031

               -  SWOG-9126

               -  SWOG-9333

               -  SWOG-9500

          -  Cryopreserved pretreatment cell specimens* available from a subset of patients (those
             who obtained a complete response [CR] and remained in CR without relapse for â‰¥ 2 years
             vs those with resistant disease [i.e., failed to achieve CR with evidence of
             persistent AML following induction therapy]) NOTE: All specimens currently available
             in the Southwest Oncology Group Myeloid Leukemia and MDS Repository at the University
             of New Mexico

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek L. Stirewalt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheryl L. Willman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of New Mexico Cancer Center</affiliation>
  </overall_official>
  <reference>
    <citation>Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood. 2011 Oct 27;118(17):4561-6. doi: 10.1182/blood-2011-04-348888. Epub 2011 Aug 26.</citation>
    <PMID>21873548</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

